Eli Lilly的tirzepatide将心脏病风险降低38%, Eli Lilly's tirzepatide reduced heart failure risk by 38% and improved exercise capacity in a SUMMIT phase 3 trial.

Eli Lilly的减重药物Tirzepatide(Zepbound, Mounjaro)显示,在后期临床试验(SUMMIT第3阶段试验)中,在减少心脏病发作风险方面有显著改善。 Eli Lilly's weight loss drug, tirzepatide (Zepbound, Mounjaro), has shown significant improvements in reducing heart failure risks in a late-stage clinical trial, SUMMIT phase 3 trial. 与安慰剂相比,该药物将心脏衰竭的风险降低了38%。 The drug reduced the risk of heart failure outcomes by 38% compared to placebo. 它提高了锻炼能力,减少了炎症,并导致合并人口体重减少15.7%。 It improved exercise capacity, reduced inflammation, and resulted in a 15.7% weight loss in a combined population. 总体安全概况与以往的研究一致,Eli Lilly计划在今年晚些时候向美国林业发展局和其他监管机构提交联森会议试验结果。 The overall safety profile was consistent with previous studies, and Eli Lilly plans to submit the SUMMIT trial results to the U.S. FDA and other regulatory agencies later this year.